Insulin resistance and metabolic syndrome in Iraqi patients with alopecia areata
DOI:
https://doi.org/10.66344/jpad.v31i3.1699Abstract
Background One of frequent forms of hair loss in humans is alopecia areata; the disease is autoimmune in nature with a clinical course that is often variable with relapse and remission and in some severe cases it may be persistent. A number of skin diseases have been shown to be associated with insulin resistance and the first report that linked alopecia areata with insulin resistance has been described recently by some authors.
Objective Due to the lack of sufficient data in our country about the possible link between alopecia areata and insulin resistance and the high rate of metabolic syndrome and insulin resistance in our society, the planning and conduction of the current study was justified to explore such an association.
Methods The current case control study included 50 patients with alopecia areata randomly selected from the pool of patients visiting dermatology unit at Al-Diwaniyah Teaching Hospital, Al-Diwaniyah province, Iraq. In addition, the study included 40 apparently healthy control subjects with comparable age and gender distribution.
Results There was no significant difference in mean serum triglyceride (p = 0.180) but serum HDL was significantly higher in patients group in comparison with control group (p=0.006). Mean fasting blood sugar (FBS) was higher in patients than in control patients in a significant manner (p=0.032); mean insulin level was also significantly higher in patients than in control group (p=0.019); mean HOMA-IR was additionally higher in patients than in control subjects with a borderline significant value (p=0.054) and the rate of insulin resistance was significantly higher in patients than in control group, 50% versus 25%, respectively.
Conclusion There is significant association between insulin resistance and alopecia areata but the link of this skin disorder to other elements of metabolic syndrome such as obesity and hypertension need further investigations.
References
1. Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers.2017;3:17011.
2. Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options. Int J Trichology.2018;10(2):51-60.
3. Brzezińska-Wcisło L, Bergler-Czop B, Wcisło-Dziadecka D, Lis-Święty A. New aspects of the treatment of alopecia areata. Postepy Dermatol Alergol.2014;31(4):262-5.
4. Kassira S, Korta DZ, Chapman LW, Dann F. Review of treatment for alopecia totalis and alopecia universalis. Int J Dermatol.2017;56(8):801-10.
5. Hordinsky MK. Overview of alopecia areata. J Investig Dermatol Symp Proc.2013;16(1):S13-5.
6. Hegde SP, Naveen KN, Athanikar SB, Reshme P. Clinical and dermatoscopic patterns of alopecia areata: a tertiary care centre experience. Int J Trichology.2013;5(3):132-6.
7. Zhang B, Zhao Y, Cai Z, Caulloo S, McElwee KJ, Li Y, Chen X, Yu M, Yang J, Chen W, Tang X, Zhang X. Early stage alopecia areata is associated with inflammation in the upper dermis and damage to the hair follicle infundibulum. Australas J Dermatol.2013;54(3):184-91.
8. Tabara K, Kozłowska M, Jędrowiak A, Bienias W, Kaszuba A. Serum concentrations of selected proinflammatory cytokines in children with alopecia areata. Postepy Dermatol Alergol.2019;36(1):63-9.
9. Bain KA, McDonald E, Moffat F, Tutino M, Castelino M, Barton A, Cavanagh J, Ijaz UZ, Siebert S, McInnes IB, Astrand A, Holmes S, Milling SWF. Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. Br J Dermatol.2020;182(1):130-7.
10. McElwee KJ, Gilhar A, Tobin DJ, et al. What causes alopecia areata?. Exp Dermatol.2013;22(9):609-26.
11. Monselise A, Bar-On R, Chan L, Leibushor N, McElwee K, Shapiro J. Examining the relationship between alopecia areata, androgenetic alopecia, and emotional intelligence. J Cutan Med Surg.2013;17(1):46-51.
12. Bakry OA, Basha MA, El Shafiee MK, Shehata WA. Thyroid disorders associated with alopecia areata in egyptian patients. Indian J Dermatol.2014;59(1):49-55.
13. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: A systematic review. Clin Cosmet Investig Dermatol.2015;8:397–403.
14. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: A systematic review. Clin Cosmet Investig Dermatol.2015;8:397–403.
15. Lundin M, Chawa S, Sachdev A, Bhanusali D, Seiffert-Sinha K, Sinha AA, et al. Gender differences in alopecia areata. J Drugs Dermatol.2014;13:409–13.
16. Napolitano M, Megna M, Monfrecola G. Insulin resistance and skin diseases. Sci World J.2015;2015:479354.
17. Karadag A. S., Ertugrul D. T., Bilgili S. G., Takci Z., Tutal E., Yilmaz H. Insulin resistance is increased in alopecia areata patients. Cutan Ocul Toxicol.2013;32(2):102–6.
18. Shahidi-Dadras M, Bahraini N, Rajabi F, Younespour S. Patients with alopecia areata show signs of insulin resistance. Arch Dermatol Res.2019;311(7):529-33. doi: 10.1007/s00403-019-01929-6.
19. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep.2018;20(2):12.
20. Mazloomzadeh S, Karami Zarandi F, Shoghli A, Dinmohammadi H. Metabolic syndrome, its components and mortality: A population-based study. Med J Islam Repub Iran.2019;33:11.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Abbas S. Dakhil
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
